Literature DB >> 2151765

A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells.

J A Symons1, J A Eastgate, G W Duff.   

Abstract

Soluble interleukin 1 (IL 1) binding proteins were identified by gel filtration and covalent cross-linking of 125I IL 1 in normal human serum and inflammatory exudate. High molecular weight 125I IL 1 protein complexes occurred with both IL 1 alpha and IL 1 beta, however, high molecular weight binding appeared to be non-specific. One specific IL 1 beta binding protein was observed to elute at approximately 100 kDa on gel filtration when bound to 125I IL 1 beta. This complex migrated as a broad band at 60 kDa when covalently cross-linked and analyzed by SDS-PAGE. The protein did not bind 125I IL 1 alpha and 125I IL 1 beta binding was only displaceable by excess cold IL-1 beta. The production of the specific IL 1 beta binding protein was assessed in a number of cell populations. Unstimulated peripheral blood mononuclear cells (PBMNC) did not produce the binding protein, but stimulation with phytohemagglutinin (PHA) caused production within 24 hr and binding protein levels remained elevated for up to 7 days. Stimulation with lipopolysaccharide (LPS) and IL 1 alpha did not consistently induce synthesis of the binding protein. Ligand-binding studies were performed to compare solubilized EL 4 NOB.1 cell membrane IL 1 receptor (sIL 1R) with semi-purified IL 1 beta binding protein from pooled synovial fluid. The sIL 1R preparation bound ligand with an affinity of 168 pM while the IL 1 beta binding protein bound 125I IL 1 beta with an affinity of 370 pM. This protein may function as an important carrier molecule for IL 1 beta and determine its distribution and kinetics in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2151765     DOI: 10.1016/1043-4666(90)90015-l

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  12 in total

1.  Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2.

Authors:  D Deane; C J McInnes; A Percival; A Wood; J Thomson; A Lear; J Gilray; S Fleming; A Mercer; D Haig
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Preferential localization of systemically administered radiolabeled interleukin 1alpha in experimental inflammation in mice by binding to the type II receptor.

Authors:  C J van der Laken; O C Boerman; W J Oyen; M T van de Ven; R Chizzonite; F H Corstens; J W van der Meer
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Age-dependent decreases in serum soluble interleukin-1 receptor type I (sIL-1RI) in healthy individuals: a population study of serum sIL-1RI levels in Japanese subjects.

Authors:  Yoshihiro Okamoto; Mayuri Tanaka; Nobuhiro Miyahara; Mie Tanabe; Yoshimitsu Gotoh; Takuhito Nagai; Naoya Fujita; Takashi Fukui; Toshiyuki Masuzawa
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

6.  Human recombinant interleukin-1 receptor antagonist blocks bone resorption induced by interleukin-1 beta but not interleukin-1 alpha.

Authors:  R A Chole; S P Tinling; B T Faddis
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

7.  Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1.

Authors:  P Bossù; U Visconti; P Ruggiero; G Macchia; M Muda; R Bertini; C Bizzarri; A Colagrande; V Sabbatini; G Maurizi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

8.  Purification and characterization of a novel soluble receptor for interleukin 1.

Authors:  J A Symons; J A Eastgate; G W Duff
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.

Authors:  Anne M Lewis; Sheelu Varghese; Hui Xu; H Richard Alexander
Journal:  J Transl Med       Date:  2006-11-10       Impact factor: 5.531

10.  A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells.

Authors:  Madhusoodhanan Rakhesh; Moriasi Cate; Ramani Vijay; Anant Shrikant; Awasthi Shanjana
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.